Showing 4561-4570 of 5646 results for "".
- Alcon Announces Broad Retail Availability of Pataday Once Daily Relief Extra Strength in the UShttps://modernod.com/news/alcon-announces-broad-retail-availability-of-pataday-once-daily-relief-extra-strength-in-the-u-s/2478886/Alcon announced that Pataday Once Daily Relief Extra Strength is now available in-store and online at U.S. retailers following its 2020 approval by the FDA for sale over the counter (OTC). As Alcon’s third Rx-to-OTC switch in the past 12 months, Pataday Once Daily Relief Extra Strength (o
- Ophthalmic Fundraising Activity Soars in Face of Pandemichttps://modernod.com/news/ophthalmic-fundraising-activity-soars-in-face-of-pandemic/2478884/The ophthalmic market continues to expand and attract funding from investors. There were more deals in 2020 than the two previous years, and transactions totaled $8.6 billion, according to a new Market Scope report. Retina is the largest ophthalmic market sector, driven by a booming pharma
- LION Eye Group Collaborates with OCLI-Spectrum Vision Partnershttps://modernod.com/news/lion-eye-group-collaborates-with-ocli-spectrum-vision-partners/2478878/New York-based LION Eye Group announces it has entered into a collaborative agreement with OCLI-Spectrum Vision Partners (OCLI) for integrated eye care. Terms of the deal were not disclosed. “The collaboration was the result of LION’s effort to engage in high quality med
- LumiThera Announces Positive Interim Data in Visual and ERG Clinical Outcomes in the ELECTROLIGHT Pilot Study in Dry AMD Patientshttps://modernod.com/news/lumithera-announces-positive-interim-data-in-visual-and-erg-clinical-outcomes-in-the-electrolight-pilot-study-in-dry-amd-patients/2478872/LumiThera announced the interim data from the ELECTROLIGHT pilot study in dry AMD patients. A total of 23 eyes from 15 subjects with intermediate dry AMD were enrolled into the prospective clinical study and treated with PBM using the Valeda Light Delivery System (3 times per week for 3 we
- Regenxbio Announces Additional Positive Interim Phase 1/2a and Long-Term Follow-Up Data of RGX-314 for the Treatment of Wet AMDhttps://modernod.com/news/regenxbio-announces-additional-positive-interim-phase-1-2a-and-long-term-follow-up-data-of-rgx-314-for-the-treatment-of-wet-amd/2478873/Regenxbio reported additional positive interim data from Cohorts 4 and 5 of its RGX-314 phase 1/2a trial for the treatment of wet age-related macular degeneration (AMD), and Cohort 3 of its Long-Term Follow-Up (LTFU) study. RGX-314 is a potential best-in-class, one-time gene therapy for the treat
- Inspecs Launches Sustainable Botaniq Eyewear Collectionhttps://modernod.com/news/inspecs-launches-sustainable-botaniq-eyewear-collection/2478870/Inspecs has launched its own sustainable eyewear range called Botaniq. The Botaniq collection, which will initially launch with 48 SKUs across 16 styles, is designed by a team of in-house technical experts at Inspecs, using biodegradeable eyewear materials as a direct response to consumer demand
- GenSight Biologics Announces Publication of Results from Lumevoq Phase 1/2a Clinical Trial REVEAL in BioDrugshttps://modernod.com/news/gensight-biologics-announces-publication-of-results-from-lumevoq-phase-1-2a-clinical-trial-reveal-in-biodrugs/2478868/GenSight Biologics announced that the journal BioDrugs has published results from REVEAL, the phase 1/2a clinical trial that evaluated the safety of Lumevoq gene therapy in subjects with ND4 Leber Hereditary Optic Neuropathy (LHON) and determined the dose subsequently used in the ph
- Gyroscope Therapeutics Announces Positive Interim Data from Phase 1 FOCUS Trial of Investigational Gene Therapy GT005https://modernod.com/news/gyroscope-therapeutics-announces-positive-interim-data-from-phase-1-focus-trial-of-investigational-gene-therapy-gt005/2478865/Gyroscope Therapeutics announced positive interim safety, protein expression and biomarker data from the ongoing open-label phase 1/2 FOCUS clinical trial of its investigational gene therapy, GT005, in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). Inte
- Genentech: New Phase 3 Data Show Faricimab the First Investigational Injectable Eye Medicine to Extend Time Between Treatment to Up to 4 Monthshttps://modernod.com/news/new-phase-3-data-show-genentechs-faricimab-is-the-first-investigational-injectable-eye-medicine-to-extend-time-between-treatment-to-up-to-4-months/2478862/Genentech announced detailed results from four phase 3 studies of its investigational bispecific antibody, faricimab, for the treatment of diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD). The studies consistently showed that faricimab, given at intervals of up
- Oculus and Myopia Profile Aim to Increase Knowledge on Myopiahttps://modernod.com/news/oculus-and-myopia-profile-aim-to-increase-knowledge-on-myopia/2478860/Myopia Profile and Oculus have commenced a partnership to increase ECP knowledge and clinical confidence in measurement and interpretation of axial length in myopia. Specific educational content, research summaries and case studies will be developed, to be housed on MyopiaProfile.com and shared a